<DOC>
	<DOCNO>NCT02750501</DOCNO>
	<brief_summary>Protocol 0000498 multi center , open label study evaluate safety , tolerability fat absorption sustain Relizorb ( immobilized lipase cartridge ) use patient cystic fibrosis exocrine pancreatic insufficiency receive enteral tube feeding .</brief_summary>
	<brief_title>Absorption Safety With Sustained Use Relizorb Evaluation ( ASSURE ) Study</brief_title>
	<detailed_description>At study entry ( Day -14 ) , blood urine collect screen assess baseline plasma erythrocyte membrane concentration docosahexaenoic acid ( DHA ) eicosapentaenoic ( EPA ) , plasma concentration long chain fatty acid , fat-soluble vitamin , serum protein urinary leukotriene concentration . Body weight body mass index obtain . During initial 7 day observation period ( Day -14 Day -8 ) , subject follow usual enteral nutrition regimen , include use pancreatic enzyme replacement therapy ( PERT ) . During 7 day run period ( Day -7 Day -1 ) , subject use Peptamen 1.5 normal volume administration 500 mL 1,000 mL per feed follow normal PERT regimen . On baseline Day 1 , subject receive Impact Peptide maximum volume 1,000 mL per feed 90 day treatment period Relizorb . Blood urine collect repeat screen concentration measurement . Standard use PERT allow daily meal permit use Relizorb enteral feeding . Safety tolerability assess use gastrointestinal symptom diary , adverse event unanticipated adverse device effect .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>1 . Confirmed diagnosis cystic fibrosis 2 clinical feature 2 . Documented history exocrine pancreatic insufficiency 3 . Enteral formula use minimum 4x/week , use PERT , consume unrestricted fat diet , willing use Peptamen 1.5 Impact Peptide 1.5 4 . Written inform consent assent . 1 . Uncontrolled diabetes mellitus 2 . Signs symptoms liver cirrhosis portal hypertension 3 . Lung liver transplant 4 . Active cancer currently receive cancer treatment 5 . Crohn 's celiac disease , infectious gastroenteritis , sprue , lactose intolerance , inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>